Suspended
Effectiveness and Safety Study of Pegamotecan (PEG-Camptothecin) in Patients With Locally Advanced or Metastatic Cancer of the Stomach or Gastroesophageal Junction Who Have Relapsed or Progressed Following a Previous Chemotherapy Treatment
What is being tested
Data Collection
Who is being recruted
Digestive System Diseases+5
+ Digestive System Neoplasms
+ Gastrointestinal Diseases
Over 18 Years
+23 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 2
Interventional
Study Start: December 2003
Summary
Principal SponsorEnzon Pharmaceuticals, Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: December 1, 2003
Actual date on which the first participant was enrolled.The purpose of this study is to evaluate the safety and efficacy of pegamotecan (PEG-camptothecin) in patients with pathologically-diagnosed locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction who have relapsed or progressed following one prior chemotherapy treatment regimen.
Official TitleEffectiveness and Safety Study of Pegamotecan (PEG-Camptothecin) in Patients With Locally Advanced or Metastatic Cancer of the Stomach or Gastroesophageal Junction Who Have Relapsed or Progressed Following a Previous Chemotherapy Treatment
Principal SponsorEnzon Pharmaceuticals, Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Digestive System DiseasesDigestive System NeoplasmsGastrointestinal DiseasesGastrointestinal NeoplasmsNeoplasmsNeoplasms by SiteStomach DiseasesStomach Neoplasms
Criteria
11 inclusion criteria required to participate
Pathologically confirmed diagnosis of adenocarcinoma of the stomach or gastroesophageal junction.
Disease measurable in at least one dimension.
Target tumors outside of prior radiation field(s).
An Eastern Cooperative Oncology Group (ECOG) performance scale score of 0 or 1
Show More Criteria
12 exclusion criteria prevent from participating
Concurrent serious medical illness unrelated to tumor within the past 6 months.
Known chronic infectious disease, such as AIDS or hepatitis (screening for hepatitis and HIV will not be performed).
Positive screening pregnancy test or is breast-feeding.
Female or male subject of reproductive capacity who is unwilling to use methods appropriate to prevent pregnancy during the course of this study.
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has no location dataSave this study to your profile to know when the location data is available.
SuspendedNo study centers